ECTRIMS

The MStranslate team recently attended the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2024, held in Copenhagen, Denmark, between September 17 and 20. As he has...

Prior to the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022, held in Amsterdam, The Netherlands, we announced that our co-founder, Brett Drummond, had been invited...

Following the success of The ECTRIMS Podcast 2022 and its subsequent episodes throughout 2023, the European Committee for Treatment and Research in Multiple Sclerosis organisation once again invited our...

MS Milan 2023 was the 9th Joint ECTRIMS-ACTRIMS Meeting, coordinated by the European Congress for the Treatment and Research Into Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and...

Late in 2022, we published two new videos that provided insights on the topic of remyelination research in multiple sclerosis (MS). The first video was recorded at the European Committee for Treatment and...

At the recent European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, Belinda Bardsley (Austin Health, Australia) presented on a research study that assessed the impact...

The 38th meeting of the European Congress for the Treatment and Research Into Multiple Sclerosis (ECTRIMS) took place in Amsterdam, The Netherlands, between the 26th and 28th of October, 2022. The ECTRIMS...

In his first feature as an official member of the MStranslate team, Novoron Bioscience CEO, Dr Travis Stiles, recently sat down with our co-founder, Brett Drummond, to discuss the latest developments in...

Due to the ongoing challenges and restrictions of the COVID-19 pandemic, ECTRIMS Congress 2021 was once again held as a virtual conference this year.  Taking place between October 13 and 15, this meeting...

EXCLUSIVE INTERVIEW At ECTRIMS Congress 2019, we had the privilege of interviewing Prof. Dimitrios Karussis (Neurologist, Hadassah Hospital) about the exciting results from his mesenchymal stem cell trial...